EAACI Congress 2024
BackJMA Poster session 01 - Allergen immunotherapy/Biologicals
Friday 31 May, 16:45 PM -
18:15 PM Valencia, Spain
Poster Zone
JMA Sessions
16:45
5-year patient-reported outcomes after oral immunotherapy using heat-modified peanuts: results from the BOPI (Boiled Peanut Oral Immunotherapy) study
16:45
A New Immunotoxin Design against Allergy Based on the IL33 Cytokine and the Ribotoxin α-Sarcin
16:45
A proof-of-concept study on an artificial intelligence model for biological therapy decision-making in severe asthma
16:45
Abatacept to induce remission of peanut allergy during oral immunotherapy (ATARI trial): baseline peanut-specific T cell responses of participants
16:45
Dupilumab dose reduction in controlled severe atopic dermatitis and predictive factors
16:45
Effect of allergen specific immunotherapy on PFS symptoms
16:45
Fast dissociation of the IgE/FcεRI complex by engaging the Cε2 domain with allosteric, bi-specific IgE inhibitors
16:45
IgG-Epitope Mapping of Birch-Pollen Bet v 1 Allergen in Allergic and Treated Patients for the Design of Hypoallergenic Immunotherapy Allergens
16:45
Immunodeficiency spectrum in patients with severe asthma receiving biologicals
16:45
Immunotherapy with Vespa velutina nigrithorax venom: safety of ultra-rush protocol and preliminary clinical results
16:45
MRNA-delivered consensus allergens induce a neutralizing IgG response against food and pollen allergens
16:45
Mesoporous silica nanoparticles for allergy diagnosis and therapy
16:45
Missense variant KIT p.D816V suggestive of mast cell disorder predisposes to Hymenoptera venom immunotherapy treatment complications and failure
16:45
Polyclonal desensitization impairs mast cell responses in an allergen specific manner without compromising IgE signaling ability
16:45
Real-world study: safety and effectiveness of a subcutaneous glutaraldehyde, polymerized undiluted olive-grasses allergen extract
16:45
Regulation of IgE-dependent histamine production by human neutrophils
16:45
The association between baseline IgE levels and response to standard-dose omalizumab in uncontrolled chronic urticaria patients
16:45
The cross-protective activity of allergen immunotherapy-induced blocking antibodies accords with the structural identity of allergens
16:45
The effect of therapies targeting Type 2 inflammation on Neutrophil Extracellular Traps (NETs) and Extracellular Eosinophilic Traps (EETs) in severe CRSwNP
16:45
The potential role of IgE in Crohn’s disease by impairing the generation of FOXP3+ regulatory T cells by plasmacytoid dendritic cells
